| Line 384: | Line 384: | ||
*Acknowledgement: This work was supported by the National Institutes of Health [5SC3GM122628]. KP, MR, and NLN were supported in part by 5SC3GM122628. JSA was funded in part by P20GM130414, a NIH funded Center of Biomedical Research Excellence (COBRE). | *Acknowledgement: This work was supported by the National Institutes of Health [5SC3GM122628]. KP, MR, and NLN were supported in part by 5SC3GM122628. JSA was funded in part by P20GM130414, a NIH funded Center of Biomedical Research Excellence (COBRE). | ||
<br> | <br> | ||
='''Smoking Harm Reduction vs Nicotine Abstinence'''= | |||
===2021: [https://academic.oup.com/ntr/advance-article/doi/10.1093/ntr/ntab148/6322566 Reappraising Choice in Addiction: Novel Conceptualizations and Treatments for Tobacco Use Disorder]=== | |||
*Given the advent of novel, alternative tobacco products, Tobacco Use Disorder must be conceptualized within a contemporary framework that includes harm reduction and alternative outcomes. | |||
*[https://academic.oup.com/ntr/advance-article-pdf/doi/10.1093/ntr/ntab148/39068104/ntab148.pdf PDF Version] | |||
*Citation: Amanda M Palmer, PhD, Benjamin A Toll, PhD, Matthew J Carpenter, PhD, Eric C Donny, PhD, Dorothy K Hatsukami, PhD, Alana M Rojewski, PhD, Tracy T Smith, PhD, Mehmet Sofuoglu, MD, PhD, Johannes Thrul, PhD, Neal L Benowitz, MD, On Behalf of the Society for Research on Nicotine & Tobacco Treatment Network, Reappraising Choice in Addiction: Novel Conceptualizations and Treatments for Tobacco Use Disorder, Nicotine & Tobacco Research, 2021;, ntab148, doi: 10.1093/ntr/ntab148 | |||
*Acknowledgement: This research was supported by by NIH Institutional Postdoctoral Training Grant NIHT32-HL144470, NIDA grant K01DA047433 (Smith), and NCI grant K07CA214839 (Rojewski), and the Hollings Cancer Center (P30 CA138313). | |||
='''Smoking Reduction'''= | ='''Smoking Reduction'''= | ||
edits